Clinical Trial Update: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Verity-BCG for safety and efficacy in BCG-naïve patients with intermediate- and high-risk non-muscle-invasive bladder cancer. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Verity-BCG (Bacillus Calmette-Guérin intravesical therapy)

Snippet

Sponsor: Verity Pharmaceuticals Inc. | Conditions: Bladder Cancer, Bladder Cancer Recurrent | Phase 3 | Status: RECRUITING